Psoriatic Arthritis
Conference Coverage
Shingles vaccine protection lasted 5-6 years in autoimmune disease patients
Key clinical point: Protection against shingles appeared to wane between the fifth and sixth years after patients with autoimmune diseases...
Conference Coverage
Stroke risk rose in autoimmune disease patients after herpes zoster
Key clinical point: Stroke risk increased by 50% in the month after patients with autoimmune diseases had an episode of herpes zoster. Major...
Conference Coverage
Can bariatric surgery ease psoriasis too?
Bariatric surgery in obese patients may lessen the symptoms of psoriasis and psoriatic arthritis.
Conference Coverage
EADV: No cancer signal with ixekizumab
To date, ixekizumab doesn’t raise any malignancy concerns in studies in psoriasis patients.
Conference Coverage
EADV: Secukinumab shows sustained high efficacy in SCULPTURE through 3 years
Key clinical point: Three-year data from a phase III trial provide reassurance regarding the long-term safety and efficacy of secukinumab for...
Conference Coverage
EADV: Spotlight on alexithymia in psoriasis
Key clinical point: Alexithymia is strikingly common among psoriasis patients and is associated with multiple psychiatric comorbidities and...
Conference Coverage
EADV: Long-term apremilast results show what to expect for psoriasis
Patients on apremilast for moderate to severe plaque psoriasis can reasonably anticipate a 50%-plus likelihood of a PASI-75 response after 52...
Conference Coverage
EADV: Ixekizumab promising for psoriatic arthritis
Key clinical point: The IL-17A inhibitor ixekizumab appears to be dramatically effective in psoriatic arthritis as well as in psoriasis. Major...
Conference Coverage
EADV: Investigational biologic rocks psoriasis world
An investigational inhibitor of the p19 subunit of interleukin-23 is generating efficacy results never before seen in psoriasis.
News
Infections from endemic fungi, mycobacteria rare in patients on TNFIs
Key clinical point: The incidence of select mycobacterial and fungal infections in patients taking TNFIs is low. Major finding: Only 0.51% of...
News
Topical calcipotriene-betamethasone combination approved for plaque psoriasis
A combination of calcipotriene and betamethasone dipropionate in a foam formulation has been approved by the Food and Drug Administration for the...